Dr. Mary Rodgers, Ph.D., Principal Scientist, Diagnostics
As a principal scientist in Abbott's diagnostics business, Mary Rodgers manages the Abbott Global Viral Surveillance Program and external collaborations for the infectious disease research division.
Abbott's Global Surveillance Program was established more than two decades ago to detect and actively monitor emerging HIV and hepatitis strains around the world. By monitoring the diversity of current epidemics as well as the next public health threats, this program serves as the scientific foundation upon which Abbott's diagnostic tests are built.
In 2019, Mary and a team of Abbott scientists announced the discovery of a new subtype of HIV and made the sequence available to the global research community. This research marked the first time in 19 years that a new subtype of HIV-1 Group M has been identified.
At the beginning of the pandemic in 2020, Mary and her team were part of the development of many COVID-19 tests – including BinaxNOW – and have been tracking the virus and its variants since then to help mitigate the spread.
Mary received her Ph.D. in biological and biomedical sciences from Harvard University. She completed her postdoctoral training at the University of Southern California. Mary joined Abbott in 2014 and has since added two new pathogens (HCV, HDV) to the Surveillance Program, published 31 research papers, and was named one of Business Insider's 30 under 40 Young Leaders in Biotech in 2017.
Mary is a member of the American Association for the Advancement of Science and the American Society of Microbiology.